Posts Tagged ‘Alzheimer’s

October 10, 2022
Our Take: Amylyx’s investigational ALS drug gains FDA approval, but the controversy continues
Read More
October 03, 2022
Our Take: Eisai, Biogen’s lecanemab slowed clinical decline by 27% in Phase III Alzheimer’s trial
Read More
July 19, 2021
Our Take: Oral arguments in Pfizer lawsuit renew focus on case that could have industry-wide implications
Read More
July 12, 2021
Our Take: As delta becomes dominant strain, U.S. COVID-19 cases increase nearly 11% in one week
Read More
June 28, 2021
Our Take: Blues plans fund new startup to address high drug prices
Read More
June 21, 2021
Our Take: Beaumont Health and Spectrum Health in talks to form a new 22-hospital health system
Read More
June 14, 2021
Our Take: FDA grants accelerated approval to Biogen’s Alzheimer’s drug, creating more controversy
Read More
October 28, 2019
Our Take: Biogen’s aducanumab gets a second life
Read More
June 03, 2019
Episode 52: Our Take, June 3, 2019
Read More
April 22, 2019
Our Take: Humana launches new oncology payment model
Read More
March 25, 2019
Our Take: A big week for Pharma
Read More

Sign up for Our Take
the weekly strategic brief for Health Care Executives

share

Reach out to us

Gainey Corporate Center
8777 N Gainey Center Dr, Ste 205
Scottsdale, AZ 85258
(480) 923-0802

Sign up for Our Take
the weekly strategic brief for Health Care Executives

[contact-form-7 id="321" title="Footer Newsletter"]

Copyright © 2025 Darwin Research Group Inc.

Stay Connected